The post-drug syndrome research library

Using electronic medical records from Northwestern Medicine, the authors tested whether longer 5-alpha-reductase inhibitor exposure raises the risk of persistent erectile dysfunction (PED, lasting at least 90 days after stopping the drug). Among 11,909…

Drawing on reports submitted to the RxISK.org adverse-event site, the authors assembled 300 cases of persistent sexual difficulty from 37 countries after treatment with serotonin reuptake inhibiting antidepressants, finasteride-type drugs, or isotretinoin…

A multidisciplinary expert panel drafted formal diagnostic criteria for four enduring post-drug conditions: PSSD, persistent genital arousal disorder after serotonin reuptake inhibitors, post-finasteride syndrome, and post-retinoid sexual dysfunction. The…

Using Israeli health-maintenance-organization (Clalit Health Services) records over a 19-year period, the authors compared 866 healthy, non-smoking men aged 21-49 who had used serotonergic antidepressants with 11,436 eligible men who had not (unmatched…

The authors reported the first atomic structure of human steroid 5-alpha-reductase 2, the enzyme finasteride inhibits, resolved at 2.8 angstroms. It revealed an unusual seven-transmembrane topology. The bound ligand was not finasteride itself but an…

Male Sprague-Dawley rats were treated with finasteride for 20 days and then followed for one month after withdrawal. At the end of treatment, the dentate gyrus showed more proliferating progenitor cells and higher hippocampal TNF-alpha mRNA, indicating an…